Exploring the Pharmacogenomic Landscape of Morocco
Pharmacogenomics (PGx) represents a transformative approach to personalized medicine, enabling healthcare practitioners to tailor therapies based on individual genetic profiles. Despite the significant advancements in PGx, North African populations, particularly Moroccans, have been largely underrepresented in global pharmacogenomic databases. This underrepresentation is concerning, given the unique genetic diversity found within these populations, which can markedly influence drug efficacy and safety. A recent study aimed to address this gap by characterizing the pharmacogenomic landscape of 109 Moroccan individuals through comprehensive whole-genome sequencing.
The research yielded a staggering 129,021 novel genetic variants across 8,289 candidate pharmacogenes, with a notable concentration of variants identified in key genes such as DPYD, CYP2C19, and SLCO1B1. These findings underscore the considerable genomic diversity present in the region and highlight the necessity for localized pharmacogenomic research. Among the 17 clinically relevant pharmacogenes examined, several variants were found to have a high prevalence, including SLCO1B1*15, UGT1A1*80 + *28, CYP2C19*17, and VKORC1 rs9923231, which are significant due to their established associations with drug response and treatment outcomes.
Furthermore, the study also encompassed HLA-A and HLA-B genotyping, revealing frequent alleles such as HLA-A*03:01, HLA-A*30:02, and HLA-B*51:01. These alleles have been previously linked to adverse drug reactions, emphasizing the importance of understanding genetic predispositions within the Moroccan population. Collectively, the findings from this research not only provide a foundational resource for interpreting pharmacogenomic data in this specific population but also pave the way for the advancement of precision medicine, contributing to improved healthcare outcomes in Morocco and the wider North African region.
The authors of the study express their gratitude to the Mohammed VI Center for Research and Innovation (CM6RI), part of the Mohammed VI Foundation for Sciences and Health, for their invaluable institutional and logistical support which facilitated the research. They also acknowledge the Clinical Pharmacogenetics Implementation Consortium (CPIC) for providing essential pharmacogenomic data that underpinned their work. This collaborative effort by researchers from institutions such as Mohammed VI University of Sciences and Health (UM6SS) and Mohammed V University (UM5) marks a significant step toward enhancing global diversity in pharmacogenomic research.
As reported by nature.com.
